Friday, July 10, 2026

pharma · Psoriasis Vulgaris · Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.

LEO Pharma US

LEO Pharma A/S is a pharma organization headquartered in Ballerup, DK. Primary therapeutic focus areas include Psoriasis Vulgaris, Moderate-to-severe plaque psoriasis and a body weight ≥120 kg., Mild to severe palmoplant

Madison, USA HQ
1908 Founded
75 Employees
EMA registrant Type
Company details
Status
Public
HQ
Madison, USA
Founded
1908
Employees
75
Programs
7
Drugs
11
Patents
0
Clinical program

LP0162-2328

Approved · small molecule · Atopic dermatitis and moderate-to severe atopic hand eczema

LP0162-2328 for Atopic dermatitis and moderate-to severe atopic hand eczema is a Approved program (small_molecule) at LEO Pharma A/S with 1 ClinicalTrials.gov record(s).

← All LEO Pharma A/S projects Approved small molecule active

Internal code LP0162-2328

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
LEO Pharma A/S
Phase
Approved
Modality
small_molecule
Indication
Atopic dermatitis and moderate-to severe atopic hand eczema
Status
active
Trials
1